The Technical Analyst
Embecta Corp. [EMBCV]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Embecta Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-9.33% $33.33
America/New_York / 1 apr 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 908.92 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 57.27 mill |
| Avg Daily Volume: | 3.48 mill |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0 - 0 ( +/- 0.00%) |
| ATR Model: 14 days |
Forecast:
01:40 - $35.54
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $33.33 (-9.33% ) |
| Volume | 0.132 mill |
| Avg. Vol. | 3.48 mill |
| % of Avg. Vol | 3.80 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EMBCV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EMBCV
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey.
Latest Press Releases
2023-05-15 17:38:00 - Press Release
Update -- Embecta To Participate In Investor Conferences
Parsippany, n.j., may 15, 2023 (globe newswire) -- embecta corp. (“embecta”) (nasdaq: embc), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following investor conferences:
2023-05-15 17:00:00 - Press Release
Embecta To Participate In Investor Conferences
Parsippany, n.j., may 15, 2023 (globe newswire) -- embecta corp. (“embecta”) (nasdaq: embc), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following investor conferences:
2023-04-20 17:00:00 - Press Release
Embecta To Report Fiscal Second Quarter 2023 Financial Results
Parsippany, n.j., april 20, 2023 (globe newswire) -- embecta corp. (“embecta”) (nasdaq: embc), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal second quarter 2023 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. eastern time (et) on friday, may 12, 2023.
2023-02-08 17:00:00 - Press Release
Embecta To Participate In Upcoming Investor Conferences
Parsippany, n.j., feb. 08, 2023 (globe newswire) -- embecta corp. (“embecta”) (nasdaq: embc), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following upcoming investor conferences:
2023-01-24 17:00:00 - Press Release
Embecta To Report Fiscal First Quarter 2023 Financial Results
Parsippany, n.j., jan. 24, 2023 (globe newswire) -- embecta corp. (“embecta”) (nasdaq: embc), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal first quarter 2023 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. eastern time (et) on tuesday, february 14, 2023.
Latest News
2024-02-09 11:43:23 - The Motley Fool
Why Embecta Stock Is Tanking Today
Embecta beat Wall Street estimates with its fiscal 2024 Q1 revenue and earnings. The company's full-year outlook, though, came in below consensus estimates.
2023-07-21 18:00:35 - Seeking Alpha
Embecta: Mammoth Effort Needed To Get Investors Over The Line, Reiterate Hold
Embecta Corp.'s stock has dropped 31% since its last publication, and analysis suggests this trend may continue. Despite securing key partnerships and signing multi-year agreements, projected revenue and earnings growth is flat. Net-net, reiterate hold on Embecta Corp.
2023-05-15 17:38:00 - GlobeNewsWire
UPDATE -- embecta to Participate in Investor Conferences
PARSIPPANY, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following investor conferences:
2023-05-15 17:00:00 - GlobeNewsWire
embecta to Participate in Investor Conferences
PARSIPPANY, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following investor conferences:
2023-04-20 17:00:00 - GlobeNewsWire
embecta to Report Fiscal Second Quarter 2023 Financial Results
PARSIPPANY, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal second quarter 2023 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, May 12, 2023.
2023-03-26 08:45:00 - The Motley Fool
3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential
Embecta should benefit from the greater need for diabetic services. Viatris is focusing on finding new generics.
2023-02-14 18:54:03 - The Motley Fool
Why Embecta Stock Popped by Nearly 13% Today
Twin beats and raised guidance make for a good day on the market for the diabetes care specialist.
2023-02-08 17:00:00 - GlobeNewsWire
embecta to Participate in Upcoming Investor Conferences
PARSIPPANY, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following upcoming investor conferences:
2023-01-24 17:00:00 - GlobeNewsWire
embecta to Report Fiscal First Quarter 2023 Financial Results
PARSIPPANY, N.J., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal first quarter 2023 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Tuesday, February 14, 2023.
2022-12-20 11:34:22 - The Motley Fool
Why Embecta Stock Is Sinking Today
